Skip to content

Netherlands Society of Gene and Cell Therapy

  • About
    • History
    • Mission
    • Board Members
    • Committees
    • Honorary Members
  • Education
    • Gene Therapy Basics
    • Cell Therapy Basics
    • Antisense Oligonucleotide Therapy Basics
    • Approved Therapies
  • Research
    • Academic Research on Gene and Cell Therapy in The Netherlands
    • Greiner Award
    • NVGCT Outstanding Achievement Award
      • 2021 NVGCT Outstanding Achievement Award
      • 2020 NVGCT Outstanding Achievement Award
      • 2019 NVGCT Outstanding Achievement Award
    • Research News
    • Human Gene Therapy
    • Other Journals
    • Useful Links
    • Research Image Gallery
    • Research vacancies
  • Events
    • Webinars
    • Calendar
    • Annual Symposium
      • Annual Symposium 2023
      • Patiënteninformatiedag Gentherapie
    • Past events
      • Annual Symposium 2022
      • Annual Symposium 2020-2021
      • Spring Symposium 2019
      • Spring Symposium 2018
  • Get Involved
    • Become a Member
    • Become a sponsor
    • Contact
  • Patient Info (NL)
    • Dossier Gentherapie Stichting BWM
    • Patiënteninformatiedag Gentherapie
    • Veelgestelde vragen
  • Sign in

Author: NVGCT

Posted on 29/03/202129/03/2021

Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial

Posted on 29/03/202129/03/2021

The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy

Posted on 26/03/202126/03/2021

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

Posted on 23/03/202123/03/2021

Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy

Posted on 23/03/202123/03/2021

Genentech Provides Update on Tominersen Program in Manifest Huntington’s Disease: Dosing to stop in Phase III clinical study of tominersen

Posts navigation

Previous page Page 1 Page 2 Page 3 … Page 5 Next page

Aankomende activiteiten

Mar
9
Thu
all-day Viruses, replicons and vaccines:... @ Koepelkerk, Amsterdam
Viruses, replicons and vaccines:... @ Koepelkerk, Amsterdam
Mar 9 all-day
 
Jun
12
Mon
all-day NVGCT Annual Symposium 2023 @ Congrescentrum de Werelt
NVGCT Annual Symposium 2023 @ Congrescentrum de Werelt
Jun 12 – Jun 13 all-day
NVGCT Annual Symposium 2023 @ Congrescentrum de Werelt | Lunteren | Gelderland | Netherlands
View Calendar
Add
  • Add to Timely Calendar
  • Add to Google
  • Add to Outlook
  • Add to Apple Calendar
  • Add to other calendar
  • Export to XML
  • LinkedIn
Privacy Statement Proudly powered by WordPress